Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: A novel prostate cancer marker
Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: A novel prostate cancer marker
复制标题
DOI：
10.1016/s0090-4295(97)00108-8
复制
发表时间：
1997-06-01
期刊：
影响因子：
2.1
通讯作者：
Bostwick, DG
中科院分区：
文献类型：
--
作者：
Darson, MF;Pacelli, A;Bostwick, DG
目标。我们描述了一种潜在的新肿瘤标志物人腺激肽释放酶 2 (hK2) 的表达，它可能在前列腺癌的诊断和监测中作为前列腺特异性抗原 (PSA) 的辅助手段。方法。我们评估了 Mayo Clinic 取出的 257 例根治性前列腺切除术标本，其中含有病理性 T2 期腺癌，以比较良性组织、高级别前列腺上皮内瘤变 (PIN) 和腺癌中 hK2、PSA 和前列腺酸性磷酸酶 (PAP) 的细胞质表达。使用了 hK2 特异性的两种单克隆抗体 hK2-A523 和 hK2-G586，以及针对 PSA (PSM-773) 和 PAP（多克隆）的抗体。结果。在每个病例中都观察到 hK2-A523、hK2-G586、PSA 和 PAP 的强烈上皮细胞质免疫反应性（分别为 100% 的病例）。两种抗体的 hK2 表达强度和范围在癌症中均高于高级别 PIN；此外，高级别 PIN 大于良性上皮。格里森原发性 4 级和 5 级癌症病例几乎在每个细胞中都显示 hK2 染色，而较低级别癌症的染色异质性更大。与 hK2 形成鲜明对比的是，PSA 和 PAP 免疫反应性在良性上皮中最为强烈，而在 PIN 和癌中染色程度较低。 hK2 和 PSA 免疫反应细胞的数量不能预测癌症复发。结论。 hK2在每种癌症中都有表达，并且表达从良性上皮到高级别PIN和腺癌逐渐增加。与 hK2 相比，PSA 和 PAP 显示出相反的免疫反应性。 hK2 和 PSA 的表达并不能预测 T2 期癌症患者的癌症复发。 hK2 的表达表明该激肽释放酶抗原既位于前列腺又与肿瘤相关。 hK2 的组织表达似乎独立于 PSA 和 PAP 进行调节。需要进一步的研究来确定 hK2 的组织免疫反应性是否将在临床上证明对前列腺癌的诊断和监测有用。 (C) 1997，爱思唯尔科学公司。
Objectives. We describe the expression of a potentially new tumor marker, human glandular kallikrein 2 (hK2), that may be useful as an adjunct to prostate-specific antigen (PSA) in the diagnosis and monitoring of prostate cancer.Methods. We evaluated 257 radical prostatectomy specimens removed at the Mayo Clinic with pathologic Stage T2 adenocarcinoma to compare the cytoplasmic expression of hK2, PSA, and prostatic acid phosphatase (PAP) in benign tissue, high-grade prostatic intraepithelial neoplasia (PIN), and adenocarcinoma. Two monoclonal antibodies, hK2-A523 and hK2-G586, specific for hK2 were used, as well as antibodies against PSA (PSM-773) and PAP (polyclonal).Results. Intense epithelial cytoplasmic immunoreactivity was observed in every case for hK2-A523, hK2-G586, PSA, and PAP (100% of cases, respectively). The intensity and extent of hK2 expression for both antibodies were greater in cancer than high-grade PIN; furthermore, high-grade PIN was greater than benign epithelium. Cases of Gleason primary grade 4 and 5 cancer showed hK2 staining in almost every cell, whereas there was greater heterogeneity of staining in lower grades of cancer. In marked contrast to hK2, PSA and PAP immunoreactivity was most intense in benign epithelium and stained to a lesser extent in PIN and carcinoma. The number of immunoreactive cells for hK2 and PSA was not predictive of cancer recurrence.Conclusions. hK2 was expressed in every cancer, and the expression incrementally increased from benign epithelium to high-grade PIN and adenocarcinoma. PSA and PAP displayed inverse immunoreactivity compared with hK2. The expression of hK2 and PSA was not predictive of cancer recurrence in patients with Stage T2 carcinoma. Expression of hK2 indicates that this kallikrein antigen is both prostate localized and tumor associated. Tissue expression of hK2 appears to be regulated independently of PSA and PAP. Further studies are needed to determine whether tissue immunoreactivity of hK2 will prove clinically useful in the diagnosis and monitoring of prostate cancer. (C) 1997, Elsevier Science Inc.